The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Paraoxon results in increased phosphorylation of ACHE protein Paraoxon results in increased expression of ACHE protein 1,3-bis(2-hydroxyiminomethylpyridinium)propane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1,4-bis(2-hydroxyiminomethylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-((4-(aminocarbonyl)pyridinio)trimethylene)-2-((hydroxyimino)methyl)pyridinium inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)but-2-ene inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-3-pyridiniumpropane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 4-(aminocarbonyl)-1-(3-(4-((E)-(hydroxyimino)methyl)pyridinium-1-yl)propyl)pyridinium dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 4-amino-2-((diethylamino)methyl)phenol analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [alpha-Tocopherol co-treated with Paraoxon] results in decreased activity of ACHE protein; [Paraoxon co-treated with Dichlorvos] results in decreased activity of ACHE protein; [Polyethylene Glycols binds to PON1 protein] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Amodiaquine analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; asoxime chloride affects the reaction [Paraoxon results in decreased activity of ACHE protein]; asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Atropine inhibits the reaction [Paraoxon results in increased expression of ACHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Cholinesterase Reactivators inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; Fullerenes analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Glucosides inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; HLo 7 inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; HS 3 inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; isonitrosoacetone inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; isonitrosoacetone inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; K075 compound inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; K117 compound inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; K127 compound inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; methamidophos promotes the reaction [Paraoxon results in decreased activity of ACHE protein]; Metoclopramide inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; Metoclopramide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Paraoxon binds to and results in decreased activity of ACHE protein; Paraoxon promotes the reaction [methamidophos results in decreased activity of ACHE protein]; Paraoxon results in decreased expression of and results in decreased activity of ACHE protein; PON1 protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein mutant form]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridine-2-aldoxime analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridine-4-aldoxime analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridine-4-aldoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pyridoxaloxime analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; RS194B analog inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; RS194B inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; RS41A inhibits the reaction [Paraoxon binds to and results in decreased activity of ACHE protein]; Tiapamil Hydrochloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; trimethylene-bis(4-hydroxyiminomethylpyridinium) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] ACHE protein inhibits the reaction [Paraoxon results in decreased expression of MCL1 polyA tail]; ACHE protein inhibits the reaction [Paraoxon results in increased abundance of Corticosterone]; Atropine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; coumarin inhibits the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; Gallamine Triethiodide promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; HLo 7 inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Paraoxon results in increased phosphorylation of and results in decreased activity of ACHE protein; Propidium promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein] Paraoxon results in decreased expression of ACHE mRNA Paraoxon results in increased acylation of ACHE protein Paraoxon results in increased activity of ACHE protein 1,4-bis(2-hydroxyiminomethylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; 1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium)butane inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Atropine co-treated with Obidoxime Chloride] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Paraoxon co-treated with pralidoxime co-treated with Atropine] results in decreased activity of ACHE protein; asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [[Paraoxon co-treated with pralidoxime co-treated with Atropine] results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Ranitidine affects the reaction [Paraoxon results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [Paraoxon results in decreased activity of ACHE protein] Paraoxon results in decreased activity of ACHE protein; Paraoxon results in decreased activity of ACHE protein mutant form
Paraoxon binds to ALB protein ALB protein results in decreased susceptibility to Paraoxon ALB protein results in decreased susceptibility to [Paraoxon results in decreased activity of BCHE protein] ALB protein results in increased hydrolysis of Paraoxon
benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased expression of and affects the localization of BAX protein]; Paraoxon results in increased expression of and affects the localization of BAX protein Paraoxon results in increased expression of BAX mRNA; Paraoxon results in increased expression of BAX protein
ALB protein results in decreased susceptibility to [Paraoxon results in decreased activity of BCHE protein]; Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; asoxime chloride inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; BCHE protein inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Glucosides inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Metoclopramide inhibits the reaction [Paraoxon binds to and results in decreased activity of BCHE protein]; Obidoxime Chloride inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Paraoxon binds to and results in decreased activity of BCHE protein; pralidoxime inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; pyridine-4-aldoxime inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; pyridoxaloxime analog inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Ranitidine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Tiapamil Hydrochloride inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]; Trimedoxime inhibits the reaction [Paraoxon results in decreased activity of BCHE protein] Paraoxon results in decreased activity of BCHE mRNA; Paraoxon results in decreased activity of BCHE protein Paraoxon binds to BCHE protein; Paraoxon binds to BCHE protein modified form BCHE protein results in decreased susceptibility to Paraoxon
Paraoxon results in decreased expression of BCL2 mRNA Paraoxon results in decreased expression of BCL2 mRNA; Paraoxon results in decreased expression of BCL2 protein
Paraoxon results in increased expression of CAPN1 protein Egtazic Acid inhibits the reaction [Paraoxon results in increased expression of CAPN1 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of CAPN1 protein]; Procaine inhibits the reaction [Paraoxon results in increased expression of CAPN1 protein]
Paraoxon results in increased expression of CAPN2 protein Egtazic Acid inhibits the reaction [Paraoxon results in increased expression of CAPN2 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of CAPN2 protein]; Procaine inhibits the reaction [Paraoxon results in increased expression of CAPN2 protein]
Egtazic Acid inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP12 protein]; Egtazic Acid inhibits the reaction [Paraoxon results in increased expression of CASP12 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP12 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of CASP12 protein]; Paraoxon results in increased expression of and affects the activity of CASP12 protein; Procaine inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP12 protein]; Procaine inhibits the reaction [Paraoxon results in increased expression of CASP12 protein]
Paraoxon results in increased activity of CASP3 protein Ro 31-8220 inhibits the reaction [Paraoxon results in increased activity of CASP3 protein] benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP3 protein]; Egtazic Acid inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP3 protein]; Heparin inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP3 protein]; Metoclopramide inhibits the reaction [Paraoxon results in increased activity of and results in increased cleavage of CASP3 protein]; Paraoxon results in increased activity of and results in increased cleavage of CASP3 protein; Paraoxon results in increased cleavage of and results in increased activity of CASP3 protein; Paraoxon results in increased expression of and affects the activity of CASP3 protein; Procaine inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP3 protein] Cyclosporine inhibits the reaction [Paraoxon results in increased activity of CASP3 protein] Paraoxon results in increased expression of CASP3 mRNA; Paraoxon results in increased expression of CASP3 protein
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein]; Paraoxon results in increased cleavage of and results in increased activity of CASP8 protein
benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased cleavage of and results in increased activity of CASP9 protein]; Paraoxon results in increased cleavage of and results in increased activity of CASP9 protein
Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein] Paraoxon results in decreased expression of CHRNA4 mRNA; Paraoxon results in decreased expression of CHRNA4 protein
Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein]]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein] Paraoxon results in decreased expression of CHRNB2 mRNA; Paraoxon results in decreased expression of CHRNB2 protein
Paraoxon results in increased activity of F2 protein [Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in decreased expression of F2 mRNA; [Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in increased activity of F2 protein
[Egtazic Acid co-treated with Paraoxon] results in increased expression of HSPA5 protein; [Procaine co-treated with Paraoxon] results in increased expression of HSPA5 protein
ACHE protein inhibits the reaction [Paraoxon results in decreased expression of MCL1 polyA tail] Paraoxon results in increased expression of MCL1 protein alternative form
Paraoxon results in increased activity of PON1 protein PON1 protein results in increased hydrolysis of Paraoxon PON1 3' UTR SNP affects the hydrolysis of Paraoxon; PON1 intron SNP affects the hydrolysis of Paraoxon; PON1 protein polymorphism affects the hydrolysis of Paraoxon PON1 gene polymorphism affects the susceptibility to Paraoxon PON1 protein results in increased metabolism of Paraoxon PON1 protein affects the metabolism of Paraoxon; PON1 protein polymorphism affects the metabolism of Paraoxon PON1 protein mutant form results in decreased susceptibility to Paraoxon PON1 protein mutant form results in increased hydrolysis of Paraoxon; PON1 protein results in increased hydrolysis of Paraoxon 2-hydroxyquinoline inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; 4-hydroxy-2-nonenal inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with Copper Sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Paraoxon; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Paraoxon; [Polyethylene Glycols binds to PON1 protein] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Polyethylene Glycols binds to PON1 protein] which results in increased hydrolysis of Paraoxon; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Calcium Chloride promotes the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Hydrogen Peroxide inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; lysophosphatidylglycerol inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; lysophosphatidylinositol inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Oleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Oxygen promotes the reaction [PON1 protein affects the metabolism of Paraoxon]; palmitoleic acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; PON1 protein inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; PON1 protein polymorphism affects the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Pyruvaldehyde inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] [Alendronate results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Paraoxon; [Clodronic Acid results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Paraoxon; [Ibandronic Acid results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Pamidronate results in decreased activity of PON1 protein] which results in decreased metabolism of Paraoxon; [Risedronic Acid results in increased activity of PON1 protein] which results in increased metabolism of Paraoxon; Fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] PON1 results in decreased susceptibility to Paraoxon
Paraoxon results in increased expression of SLC1A2 mRNA; Paraoxon results in increased expression of SLC1A2 protein Paraoxon affects the expression of SLC1A2 mRNA; Paraoxon affects the expression of SLC1A2 protein
Paraoxon results in increased expression of SLC1A3 mRNA; Paraoxon results in increased expression of SLC1A3 protein Paraoxon affects the expression of SLC1A3 mRNA; Paraoxon affects the expression of SLC1A3 protein
Paraoxon results in increased expression of TRP53 protein benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane analog inhibits the reaction [Paraoxon results in increased expression of TRP53 protein]
browse the term
